论文部分内容阅读
目的探讨帕尼培南/倍他米隆对儿童血液肿瘤合并粒细胞缺乏感染患者进行治疗的临床疗效。方法对2013年1月-2015年12月医院住院期间应用帕尼培南/倍他米隆治疗的203例血液肿瘤合并粒细胞缺乏的感染病例进行回顾性研究,分析帕尼培南/倍他米隆对血液肿瘤合并粒细胞缺乏感染患儿的治疗疗效、细菌学清除率以及不良反应发生率。结果帕尼培南/倍他米隆临床治疗总有效率为87.1%,对合并不同部位感染有效率均>80.0%,细菌总清除率87.5%,不良反应发生率2.0%。结论帕尼培南/倍他米隆对血液肿瘤合并粒细胞缺乏的感染患儿治疗安全有效。
Objective To investigate the clinical efficacy of panipenem / betamipron in the treatment of children with hematologic malignancies complicated with agranulocytosis. Methods A retrospective study was performed on 203 cases of neutropenia complicated with panitumin / betamron during hospitalization from January 2013 to December 2015 in our hospital. The effects of panipenem / The curative effect, bacteriological clearance rate and adverse reaction rate of Milon on children with agranulocytosis and agranulocytosis were analyzed. Results The total effective rate of clinical treatment with panipenem / betamethamine was 87.1%, the effective rates of infection in different sites were> 80.0%, the total bacterial clearance rate was 87.5% and the incidence of adverse reactions was 2.0%. Conclusions Panipenem / Betamethamine is safe and effective in the treatment of children with hematologic malignancies complicated with agranulocytosis.